Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 21822305)

1.

Macrophages and therapeutic resistance in cancer.

Ruffell B, Coussens LM.

Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub 2015 Apr 6. Review.

PMID:
25858805
2.

Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.

Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S.

Nat Cell Biol. 2015 Feb;17(2):170-82. doi: 10.1038/ncb3090. Epub 2015 Jan 12.

PMID:
25580734
3.

Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.

Wei IH, Harmon CM, Arcerito M, Cheng DF, Minter RM, Simeone DM.

Ann Surg. 2014 Dec;260(6):1088-94. doi: 10.1097/SLA.0000000000000262.

4.

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression.

Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G.

Front Immunol. 2014 Oct 7;5:489. doi: 10.3389/fimmu.2014.00489. eCollection 2014. Review.

5.

Tumor-associated macrophages as major players in the tumor microenvironment.

Chanmee T, Ontong P, Konno K, Itano N.

Cancers (Basel). 2014 Aug 13;6(3):1670-90. doi: 10.3390/cancers6031670. Review.

6.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31.

PMID:
25082815
7.

Targeting tumor-infiltrating macrophages to combat cancer.

Panni RZ, Linehan DC, DeNardo DG.

Immunotherapy. 2013 Oct;5(10):1075-87. doi: 10.2217/imt.13.102. Review.

8.

Premetastatic soil and prevention of breast cancer brain metastasis.

Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H.

Neuro Oncol. 2013 Jul;15(7):891-903. doi: 10.1093/neuonc/not031. Epub 2013 Apr 17.

9.

SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness.

Lin HY, Amankwah EK, Tseng TS, Qu X, Chen DT, Park JY.

PLoS One. 2013 Apr 3;8(4):e59688. doi: 10.1371/journal.pone.0059688. Print 2013.

10.

Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.

Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA.

PLoS One. 2013;8(1):e54302. doi: 10.1371/journal.pone.0054302. Epub 2013 Jan 23.

11.

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG.

Cancer Res. 2013 Feb 1;73(3):1128-41. doi: 10.1158/0008-5472.CAN-12-2731. Epub 2012 Dec 5.

12.

Anti-tumour strategies aiming to target tumour-associated macrophages.

Tang X, Mo C, Wang Y, Wei D, Xiao H.

Immunology. 2013 Feb;138(2):93-104. doi: 10.1111/imm.12023. Review.

13.

Differential macrophage programming in the tumor microenvironment.

Ruffell B, Affara NI, Coussens LM.

Trends Immunol. 2012 Mar;33(3):119-26. doi: 10.1016/j.it.2011.12.001. Epub 2012 Jan 23. Review.

14.

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA.

Genes Dev. 2011 Dec 1;25(23):2465-79. doi: 10.1101/gad.180331.111.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk